...
首页> 外文期刊>Vaccine >Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
【24h】

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

机译:估计抗肺炎球菌荚膜多糖抗体的保护浓度

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Estimates of minimum protective antibody concentrations for vaccine preventable diseases are of critical importance in assessing whether new vaccines will be as effective as those for which clinical efficacy was shown directly. We describe a method for correlating pneumococcal anticapsular antibody responses of infants immunized with pneumococcal conjugate (PnC) vaccine (Prevenar) with clinical protection from invasive pneumococcal disease (IPD). Data from three double blind controlled trials in Northern Californian, American Indian and South African infants were pooled in a meta-analysis to derive a protective concentration of 0.35 microg/ml for anticapsular antibodies to the 7 serotypes in Prevenar. This concentration has been recommended by a WHO Working Group as applicable on a global basis for assessing the efficacy of future pneumococcal conjugate vaccines. The WHO Working Groups anticipated that modifications in antibody assays for pneumococcal anticapsular antibodies would occur. The principles for determining whether such assay modifications should change the protective concentration are outlined. These principles were applied to an improvement in the ELISA for anticapsular antibodies, i.e. absorption with 22F pneumococcal polysaccharide, which increases the specificity of the assay for vaccine serotype anticapsular antibodies by removing non-specific antibodies. Using sera from infants in the pivotal efficacy trial in Northern California Kaiser Permanente (NCKP), 22F absorption resulted in minimal declines in pneumococcal antibody in Prevenar immunized infants but significant declines in unimmunized controls. Recalculation of the protective concentration after 22F absorption resulted in only a small decline from 0.35 microg/ml to 0.32 microg/ml. These data support retaining the 0.35 microg/ml minimum protective concentration recommended by WHO for assessing the efficacy of pneumococcal conjugate vaccines in infants.
机译:疫苗可预防疾病的最低保护性抗体浓度的估计对于评估新疫苗是否与直接显示临床功效的疫苗一样有效至关重要。我们描述了一种方法,将肺炎球菌结合物(PnC)疫苗(Prevenar)免疫的婴儿的肺炎球菌抗荚膜抗体反应与侵袭性肺炎球菌疾病(IPD)的临床保护相关联。来自北加州,美洲印第安人和南非婴儿的三项双盲对照试验的数据汇总进行荟萃分析,得出针对Prevenar中7种血清型的抗荚膜抗体的保护性浓度为0.35微克/毫升。世卫组织工作组已建议在全球范围内适用这种浓度,以评估未来的肺炎球菌结合疫苗的功效。世卫组织工作组预计,肺炎球菌抗荚膜抗体的抗体检测方法将会发生变化。概述了确定此类测定方法是否应改变保护浓度的原理。这些原理可用于抗荚膜抗体的ELISA的改进,即用22F肺炎球菌多糖吸收,从而通过去除非特异性抗体而提高了疫苗血清型抗荚膜抗体测定的特异性。在北加州Kaiser Permanente(NCKP)的关键功效试验中,使用婴儿血清进行22F吸收后,Prevenar免疫婴儿的肺炎球菌抗体下降最小,而未免疫对照的肺炎球菌抗体显着下降。在吸收22 F后重新计算保护浓度,仅从0.35微克/毫升小幅下降至0.32微克/毫升。这些数据支持保留WHO推荐的0.35 microg / ml最低保护浓度,以评估婴儿肺炎球菌结合疫苗的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号